China National Pharmaceutical Group acquires innovative drug company Hegia with a maximum base price of 1.2 billion RMB

SINO BIOPHARM (01177.HK) has entered into a sales agreement to acquire 100% equity of Hejiya, with a maximum base price of RMB 1.2 billion, to be paid partially in cash and partially in equity shares.

The company stated that Hejiya is a pioneering biopharmaceutical enterprise focused on the research and development of small interfering RNA (siRNA) innovative drugs. It has established an integrated innovative drug development system from target discovery to clinical proof of concept (POC), with a focus on three major chronic disease areas: weight loss metabolism, cardiovascular and cerebrovascular, and nervous system. Hejiya has 4 clinical-stage assets and over 10 preclinical assets, all of which have first-in-class and best-in-class potential